Yann Echelard has served as rEVO’s chief executive officer and a member of the board of directors since May 2012 and has held various positions with the Company since January 1994 when it was known as Genzyme Transgenics Corporation, including vice president of research and development and vice president of corporate and technology development. Dr. Echelard spearheaded the creation of a collaborative joint venture with LFB Biotech in 2006. This close collaboration led to the acquisition of the company by LFB Biotech in December 2010. Dr. Echelard currently serves as a director of TG Therapeutics (NASDAQ: TGTX) and as a director of GTC Biotherapeutics UK Limited, a subsidiary of LFB USA.
Dr. Echelard holds a Ph.D. in Microbiology and Immunology from the Université de Montréal and has completed post-doctoral studies at the Ludwig Institute of Cancer Research (at McGill University), the Roche Institute (Nutley, NJ) and Harvard University.
President and CEO